Minerva Neurosciences, Inc · NASDAQ:NERV
Minerva Neurosciences — Investor Presentation (September 2014)
15 slides from Minerva Neurosciences's investor presentation, Sep 4, 2014
Slide 1: Dedicated to transforming the lives of people affected by neuropsychiatric diseases
Exhibit 99.1 September 4, 2014 Dedicated to transforming the lives of people affected by neuropsychiatric diseases through innovative science that addresses patients’ unmet needs Rogerio Vivaldi, MD President & CEO
Slide 2: Forward-Looking Statement Safe-Harbor
Forward-Looking Statement Safe-Harbor 2 This presentation contains certain forward-looking statements about Minerva Neurosciences that are intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-
Slide 3: The Minerva Story: A company for all stakeholders
The Minerva Story: A company for all stakeholders: patients, investors, science and beyond 3 Represents patients in the seven major markets (U.S., Japan, France, Germany, Italy, Spain and the United Kingdom) Datamonitor, Decision Resources. Represents 2012 Drug Sales Portfolio of First in Class Neur
Slide 4: Proven Leadership Team & External R&D
Proven Leadership Team & External R&D 4 Rogerio Vivaldi, MD, MBA President & CEO Launched & commercialized 20 drugs for unmet medical needs in the last 20 years.Built Genzyme in Latin America Remy Luthringer, PhD EVP & Head of R&D Conducted over 750 clinical studies in neuropsychiatry space Geoff Ra
Slide 5: Pipeline: Transformative Therapies
Pipeline: Transformative Therapies Next generation of first in class neuropsychiatry pharmaceuticals 5 Ph IIB TBD Ph IIB Starts in Q4 14 Ph IB ongoing Ph I TBD Phase I Completed Phase IIA Completed Once a Day Formulation ongoing Phase IA Completed Preclinical ongoing 90M $14B 1. Source: Datamonitor
Slide 6: MIN-101: Potential first in class transformative schizophrenia therapy
MIN-101: Potential first in class transformative schizophrenia therapy 6 Potential to be the first drug to treat negative disease symptoms While potentially addressing the entire spectrum of symptoms Potential to avoid severe side effects of existing therapies Sedation, involuntary movements, prolac
Slide 7: MIN-101 Mechanism of Action
MIN-101 Mechanism of Action 7
Slide 8: Dopamine Modulation
pamine Modulati: MINERVA
Slide 9: MIN-101: Compelling Efficacy on Spectrum of Symptoms (Phase IIA)
MIN-101: Compelling Efficacy on Spectrum of Symptoms (Phase IIA) 9 Mean Changes from Baseline (around 90) Total PANSS Weighted Score Decrease: -24.1 for MIN-101 versus -17.9 Placebo Placebo Placebo Placebo Placebo Placebo p < 0.05 p = 0.08 Placebo Mean Changes from Baseline Placebo Placebo Placebo 2
Slide 10: MIN-101: Compelling Efficacy On Sleep (Phase IIA)
MIN-101: Compelling Efficacy On Sleep - Objective1 and Subjective 2 Measurements (Phase IIA) Quicker onset of sleep after 2 weeks of treatment with MIN-101 vs. Placebo 10 Objective Measures of Sleep Onset (By PSG) Subjective Measures By PSQI Scale MIN-101 Placebo MIN-101 Placebo Day 84 Day 84 Mean +
Slide 11: Phase IIB Study Design; Results Expected 1H 2016
1H 2016 Phase IIB Results Expected to be submitted in 4Q 2014 – Phase IIB Multicenter, randomized, double-blind, placebo controlled, parallel group design study in approximately 234 schizophrenic patients with predominantly negative symptoms, randomized in a 1:1:1 ratio to receive MIN-101 64 mg, MIN
Slide 12: Huge Commercial Opportunity: Significant Unmet Medical Need in Schizophrenia
Huge Commercial Opportunity: Significant Unmet Medical Need in Schizophrenia 12 SEVERITY OF ILLNESS Chronic Progression of Negative Symptoms & Cognitive Impairment Youth 0-18 Adult 18-40 Mature >40 Cognitive Symptoms Negative Symptoms Positive Symptoms Current Treatments Focus On Positive Symptoms $
Slide 13: MIN-202: New generation of mechanism of action
MIN-202: New generation of mechanism of action 13 Blocks Wake Drive Efficacy that’s equal or superior to Standard of Care Enables true, restorative sleep Normal levels of REM sleep No residual sedation No daytime impairment Normal motion suppression No alcohol interaction No abuse potential Mechanis
Slide 14: Pipeline: Transformative Therapies
Pipeline: Transformative Therapies Next generation of first in class neuropsychiatry pharmaceuticals 14 Ph IIB TBD Ph IIB Starts in Q4 14 Ph IB ongoing Ph I TBD Phase I Completed Phase IIA Completed Once a Day Formulation ongoing Phase IA Completed Preclinical ongoing 90M $14B 1. Source: Datamonitor
Slide 15: Thank You
Dedicated to transforming the lives of people affected by neuropsychiatric diseases through innovative science that addresses patients’ unmet needs Thank You
Minerva Neurosciences — Investor Presentation (September 2014) on 6ix